Wilms' tumour and chemotherapeutic access

Sir,

We enjoy reading the recent report on 'Wilms' tumour and chemotherapeutic access'.[1] Anyanwa *et al*. reported that 'an institutionalised approach can help to improve access to anti-cancer drugs, reduce the rate of loss to follow-up and thus improve outcome'.[1] In fact, the problem of anticancer drug access can be seen in many developing countries. In a previous report by Uba and Chirdan, 'poor availability of cytotoxic drugs' is an important factor contributing to the poor outcome of disease in Nigeria.[2] It is suggested that pre-operative combined chemotherapy is required for the better operative curative outcome of paediatric cases of Wilms' tumours.[3] To manage the high cost of chemotherapy, some new studies show that metronomic chemotherapy can be the hope for the management of the problem.[4]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Sora Yasri, Viroj Wiwanitkit[1,2,3,4]

KMT Primary Care Center, Bangkok, Thailand, [1]Faculty of Medicine, University of Nis, Nis, Serbia, [2]Joseph Ayo Babalola University, Nigeria, [3]Hainan Medical University, Haikou, China, [4]Dr. D. Y. Patil Medical University, Pune, Maharashtra, India

Address for correspondence: Dr. Sora Yasri, KMT Primary Care Center, Bangkok, Thailand. E-mail: sorayasri@outlook.co.th

REFERENCES

1. Anyanwa LJ, Atanda AT, Atanda JO. Wilms' tumour in African children: Can an institutional approach improve outcome? Afr J Paediatr Surg 2015;12:7-11.
2. Uba AF, Chirdan LB. Childhood Wilms' tumour: Prognostic factors in North Central Nigeria. West Afr J Med 2007;26:222-5.
3. Suryanarayan K, Marina N. Wilms' tumour. Optimal treatment strategies. Drugs 1998;56:598-605.
4. Fousseyni T, Diawara M, Pasquier E, André N. Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01. J Pediatr Hematol Oncol 2011;33:31-4.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Access this article online	
Quick Response Code:	Website: www.afrjpaedsurg.org
	DOI: 10.4103/0189-6725.170232

Cite this article as: Yasri S, Wiwanitkit V. Wilms' tumour and chemotherapeutic access. Afr J Paediatr Surg 2015;12:208.